FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension

Exclusion Criteria

• •Renal artery anatomy failures include:
• •1. Renal artery diameter \<4mm or treatment length \<20mm;
• •2. Renal artery stenosis \>50% or renal aneurysm on either side;
• •3. A history of renal artery intervention, including balloon angioplasty or stenting or RDN;
• •Glomerular filtration rate (eGFR) \<45mL/min/1.73m2 (MDRD formula);
• •History of hospitalization for hypertensive crisis in the past year;
• •During the screening and lead-in period, the patient used antihypertensive drugs other than the standard antihypertensive drugs prescribed in this study protocol;
• •Nocturnal sleep apnea syndrome requires mechanical ventilation (such as tracheostomy);
• •Those who have or are currently suffering from the following diseases or conditions:
• •1. Primary pulmonary hypertension (moderate to severe);
• •2. Type I diabetes;
• •3. History of any cerebrovascular events (eg, stroke, transient cerebral ischemic event, cerebrovascular accident) within 3 months;
• •4. History of any serious cardiovascular event within 3 months (eg, myocardial infarction, CABG, acute heart failure requiring hospitalization (NYHA III-IV), unstable angina attack);
• •5. Factors that interfere with blood pressure measurement in any case (eg, patients with severe peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, severe anemia);
• •6. Arranged or planned surgery or cardiovascular intervention within the next 6 months;
• •7. Patients with malignant tumors and end-stage diseases who survival period is less than 1year;
• •Patients with secondary hypertension.
• •Patients who are deemed inappropriate to participate in this trial by other investigators.